Try our business solution for free!

Takeda new debts to EBITDA ratios targeted until 2023

Published by
Matej Mikulic,
Feb 12, 2019
This statistic depicts the targeted net debt to EBITDA ratio of Takeda Pharmaceutical after the Shire deal, until March 2023, by deleveraging case. The ratio of debts to EBITDA before the Shire deal in standalone deleveraging cases was 1.6.

Targeted net debt to EBITDA ratio of Takeda Pharmaceutical after Shire deal until 2023

Loading statistic...

© Statista 2023
Download
Show detailed source information?
Register for free
Already a member?
Log in
Sources

Use Ask Statista Research Service

Release date

January 2019

Region

Worldwide

Survey time period

as of January 2019

Supplementary notes

* Ratio for before Shire deal is as of March 2018.

Citation formats
Statista Accounts: Access All Statistics. Starting from $468 USD / Year
Basic Account
Get to know the platform

You only have access to basic statistics.

Starter Account
The ideal entry-level account for individual users
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references
$59 USD $39 USD / Month *
in the first 12 months
Professional Account
Full access

Business Solutions including all features.

* Prices do not include sales tax.

Statistics on " Pharmaceutical industry in Scandinavia "

The most important statistics
The most important statistics
The most important statistics
The most important statistics

Statistics on Pharmaceutical industry in Scandinavia

Pharmaceutical sales

8

Patents and clinical trials

6

Trade

5

Key players

6

Further related statistics

18

Further Content: You might find this interesting as well

Statistics

Topics

Pharmaceutical and biotech M&A activitiesGlobal pharmaceutical industryGlobal mergers and acquisitionsMergers and acquisitions in EuropeMergers and acquisitions in the United States
Statista Accounts: Access All Statistics. Starting from $468 USD / Year
Learn more about how Statista can support your business.
Menu